Ligand Pharmaceuticals Inc (NASDAQ:LGND)

During the Trading Day
102.55 +0.46 / +0.45%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
102.54 -0.0123 / -0.01%
 
Volume: 3.6K
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
11:37am / Zacks.com
Illumina Tops Q2 Earnings, Misses on Revenues; EPS View Up - Analyst Blog
Jul 22 / Zacks.com
Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog
Jul 24 / Zacks.com
Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog
Jul 21 / Zacks.com
AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
Jul 24 / Zacks.com
Bristol-Myers Inks Another Fibrotic Disease Agreement - Analyst Blog
Jul 16 / Zacks.com
Revolade Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic A...
Jul 24 / Benzinga
Novartis' Malaria Drug Gets WHO Nod for Public Procurement - Analyst Blog
Jul 16 / Zacks.com
XOMA Crashes after Gevokizumab Misses Primary Endpoint - Analyst Blog
Jul 23 / Zacks.com
Aratana's (PETX) Pain Drug for Dogs Effective in Pivotal Study - Analyst Blog
Jul 15 / Zacks.com
Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog
Jul 23 / Zacks.com
Cytokinetics Advances Tirasemtiv to Phase III, Shares Up - Analyst Blog
Jul 15 / Zacks.com
Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog
Jul 23 / Zacks.com
Why Ligand Pharmaceuticals (LGND) Could Be an Impressive Growth Stock - Tale of the T...
Jul 15 / Zacks.com
Eli Lilly Beats on 2Q Earnings by Wide Margin, Ups View - Analyst Blog
Jul 23 / Zacks.com
Qiagen's EGFR Test Gets PMA Nod to Treat Lung Cancer - Analyst Blog
Jul 14 / Zacks.com
Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
Jul 22 / Zacks.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account